PDF herunterladen
Semin Reprod Med 2003; 21(3): 277-284
DOI: 10.1055/s-2003-43305
Copyright © 2003 by Thieme Medical Publishers, Inc., 333 Seventh Avenue, New York, NY 10001, USA. Tel.: +1(212) 584-4662

Pharmacologic Treatment of Polycystic Ovary Syndrome

David A. Ehrmann1 , Daniel Rychlik2
  • 1Department of Medicine, Section of Endocrinology, The University of Chicago, Chicago, Illinois
  • 2Department of Obstetrics and Gynecology, Section of Reproductive Endocrinology, The University of Chicago, Chicago, Illinois
Weitere Informationen

Publikationsverlauf

Publikationsdatum:
31. Oktober 2003 (online)

    Lizenzen und Reprints

ABSTRACT

Women with polycystic ovary syndrome (PCOS) most often seek treatment for reduction of hair growth and/or acne, restoration of menstrual cyclicity, and infertility. In addition, these patients are increasingly seeking advise and treatment for the metabolic abnormalities related to PCOS (e.g., insulin resistance and type 2 diabetes). In this review, we outline the pathophysiologic events underlying the cutaneous manifestations of androgen excess and provide a rationale for use of the various pharmacologic agents available for treatment. Options for the treatment of the reproductive abnormalities (menstrual dysfunction and interfility) are presented. Finally, the metabolic manifestations of PCOS are reviewed and their treatment is discussed.

KEYWORDS

Polycystic ovary syndrome - hirsutism - oligomenorrhea - insulin resistance - type 2 diabetes mellitus

REFERENCES

  • 1 Kuhl H. Comparative pharmacology of newer progestogens.  Drugs . 1996;  51 188-215
    PubMedGoogle Scholar
  • 2 Krattenmacher R. Drospirenone: pharmacology and pharmacokinetics of a unique progestogen.  Contraception . 2000;  62 29-38
    CrossrefPubMedGoogle Scholar
  • 3 Mowszowicz I, Wright F, Vincens M. Androgen metabolism in hirsute patients treated with cyproterone acetate.  J Steroid Biochem . 1984;  20 757-761
    CrossrefPubMedGoogle Scholar
  • 4 Miller J, Jacobs H. Treatment of hirsutism and acne with cyproterone acetate.  Clin Endocrinol Metab . 1986;  15 373-389
    CrossrefPubMedGoogle Scholar
  • 5 Miller J, Wojnarowska F, Dowd P. Antiandrogen treatment in women with acne: a controlled trial.  Br J Dermatol . 1986;  114 705-716
    PubMedGoogle Scholar
  • 6 Barth J, Cherry C, Wojnarowska F, Dawber R. Spironolactone is an effective and well tolerated systemic antiandrogen therapy for hirsute women.  J Clin Endocrinol Metab . 1989;  68 966-970
    PubMedGoogle Scholar
  • 7 O'Brien R, Cooper M, Murray R. Comparison of sequential cyproterone acetate versus spironolactone/oral contraceptive in the treatment of hirsutism.  J Clin Endocrinol Metab . 1991;  72 1008-1013
    PubMedGoogle Scholar
  • 8 Crosby P, Rittmaster R. Predictors of clinical response in hirsute women treated with spironolactone.  Fertil Steril . 1991;  55 1076-1081
    PubMedGoogle Scholar
  • 9 Givens J. Treatment of hirsutism with spironolactone.  Fertil Steril . 1985;  43 841-843
    PubMedGoogle Scholar
  • 10 Neri R, Monahan M. Effects of a novel nonsteroidal antiandrogen on canine prostatic hyperplasia.  Invest Urol . 1972;  10 123-130
    PubMedGoogle Scholar
  • 11 Cusan L, Dupont A, Belanger A, Tremblay R, Manhes G, Labrie F. Treatment of hirsutism with the pure antiandrogen flutamide.  J Am Acad Dermatol . 1990;  23 462-469
    PubMedGoogle Scholar
  • 12 Pazos F, Escobar-Morreale H F, Balsa J, Sancho J M, Varela C. Prospective randomized study comparing the long-acting gonadotropin-releasing hormone agonist triptorelin, flutamide, and cyproterone acetate, used in combination with an oral contraceptive, in the treatment of hirsutism.  Fertil Steril . 1999;  71 122-128
    CrossrefPubMedGoogle Scholar
  • 13 Rittmaster R. Differential suppression of testosterone and estradiol in hirsute women with the superactive gonadotropin-releasing hormone agonist leuprolide.  J Clin Endocrinol Metab . 1988;  67 651-655
    PubMedGoogle Scholar
  • 14 Sidenius-Johansen J, Juel-Riis B, Hassager C, Moen M, Jacobson J, Christiansen C. The effect of a gonadotropin-releasing hormone agonist analog (nafarelin) on bone metabolism.  J Clin Endocrinol Metab . 1988;  67 701-706
    PubMedGoogle Scholar
  • 15 Matta W, Shaw R, Hesp R, Evans R. Reversible trabecular bone density loss following induced hypooestrogenism with the GnRH analogue buserelin in premenopausal women.  Clin Endocrinol (Oxf) . 1988;  29 45-51
    PubMedGoogle Scholar
  • 16 Adashi E. Potential utility of gonadotropin-releasing hormone agonists in the management of ovarian hyperandrogenism.  Fertil Steril . 1990;  53 765-779
    PubMedGoogle Scholar
  • 17 Rittmaster R, Loriaux D, Cutler G. Sensitivity of cortisol and adrenal androgens to dexamethasone suppression in hirsute women.  J Clin Endocrinol Metab . 1985;  61 462-466
    PubMedGoogle Scholar
  • 18 Steinberger E, Rodriguez-Rigau L, Weidman E, Smith K, Ayala C. Glucocorticoid therapy in hyperandrogenism.  Baillieres Clin Obstet Gynaecol . 1990;  4 457-471
    PubMedGoogle Scholar
  • 19 Azziz R, Rafi A, Smith B R, Bradley Jr L E, Zacur H A. On the origin of the elevated 17-hydroxyprogesterone levels after adrenal stimulation in hyperandrogenism.  J Clin Endocrinol Metab . 1990;  70 431-436
    PubMedGoogle Scholar
  • 20 Liang T, Rasmusson G, Brooks J. Biochemical and biological studies with 4-aza-steroidal 5α-reductase inhibitors.  J Steroid Biochem . 1983;  19 385-390
    PubMedGoogle Scholar
  • 21 Rittmaster R S. 5alpha-Reductase inhibitors.  J Androl . 1997;  18 582-587
    PubMedGoogle Scholar
  • 22 Jafari K, Tavaheri C, Ruiz G. Endometrial adenocarcinoma and the Stein-Leventhal syndrome.  Obstet Gynecol . 1978;  51 97-100
    PubMedGoogle Scholar
  • 23 Coulam C, Annegers J, Kranz J. Chronic anovulation syndrome and associated neoplasia.  Obstet Gynecol . 1983;  61 403-407
    PubMedGoogle Scholar
  • 24 Farhi D, Nosanchuk J, Silverberg S. Endometrial adenocarcinoma in women under 25 years of age.  Obstet Gynecol . 1986;  68 741-745
    PubMedGoogle Scholar
  • 25 Bayer S, DeCherney A. Clinical manifestations and treatment of dysfunctional uterine bleeding.  JAMA . 1993;  269 1823-1828
    CrossrefPubMedGoogle Scholar
  • 26 Group P TW. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women.  JAMA . 1995;  273 199-208
    CrossrefPubMedGoogle Scholar
  • 27 Woodruff J, Pickar J. Incidence of endometrial hyperplasia in postmenopausal women taking conjugated estrogens (Premarin) with medroxyprogesterone acetate or conjugated estrogens alone.  Am J Obstet Gynecol . 1994;  170 1213-1223
    PubMedGoogle Scholar
  • 28 Messinis I, Milingos S. Current and future status of ovulation induction in polycystic ovary syndrome.  Hum Reprod Update . 1997;  3 235-253
    CrossrefPubMedGoogle Scholar
  • 29 Barnes R. Diagnosis and therapy of hyperandrogenism.  Baillieres Clin Obstet Gynaecol . 1997;  11 369-396
    PubMedGoogle Scholar
  • 30 Hammond M, Halme J, Talbert L. Factors affecting the pregnancy rate in clomiphene citrate induction of ovulation.  Obstet Gynecol . 1983;  62 196-202
    PubMedGoogle Scholar
  • 31 Gysler M, March C, Mishell D, Bailey E. A decade's experience with an individualized clomiphene treatment regimen including its effects on the post-coital test.  Fertil Steril . 1982;  37 161-167
    PubMedGoogle Scholar
  • 32 Glueck C J, Phillips H, Cameron D, Sieve-Smith L, Wang P. Continuing metformin throughout pregnancy in women with polycystic ovary syndrome appears to safely reduce first-trimester spontaneous abortion: a pilot study.  Fertil Steril . 2001;  75 46-52
    CrossrefPubMedGoogle Scholar
  • 33 Sagle A, Hamilton-Fairley D, Kiddy D, Franks S. A comparative, randomized study of low-dose human menopausal gonadotropin and follicle-stimulating hormone in women with polycystic ovarian syndrome.  Fertil Steril . 1991;  55 56-60
    PubMedGoogle Scholar
  • 34 Buvat J, Buvat-Herbaut M, Marcolin G. Purified follicle-stimulating hormone in polycystic ovary syndrome: slow administration is safer and more effective.  Fertil Steril . 1989;  52 553-559
    PubMedGoogle Scholar
  • 35 Shoham Z, Patel A, Jacobs H. Polycystic ovarian syndrome: safety and effectiveness of stepwise and low-dose administration of purified follicle-stimulating hormone.  Fertil Steril . 1991;  55 1051-1056
    PubMedGoogle Scholar
  • 36 Mizunuma H, Takagi T, Yamada K. Ovulation induction by step-down administration of purified urinary follicle-stimulating hormone in patients with polycystic ovarian syndrome.  Fertil Steril . 1991;  55 1195-1196
    PubMedGoogle Scholar
  • 37 Homburg R, Levy T, Ben-Rafael Z. A comparative prospective study of conventional regimen with chronic low-dose administration of follicle-stimulating hormone for anovulation associated with polycystic ovary syndrome.  Fertil Steril . 1995;  63 729-733
    PubMedGoogle Scholar
  • 38 Brzyski R, Grow D, Sims J, Seltman H. Increase in androgen:estrogen ratio specifically during low-dose follicle-stimulating hormone therapy for polycystic ovary syndrome.  Fertil Steril . 1995;  64 693-697
    PubMedGoogle Scholar
  • 39 Hugues J, Cedrin-Durnerin I, Avril C. Sequential step-up and step-down regimen: an alternative method for ovulation induction with follicle-stimulating hormone in polycystic ovarian syndrome.  Hum Reprod . 1996;  11 2581-2584
    PubMedGoogle Scholar
  • 40 van Santbrink E, Fauser B. Urinary follicle-stimulating hormone for normogonadotropic clomiphene-resistant anovulatory infertility: prospective, randomized comparison between low dose step-up and step-down dose regimens.  J Clin Endocrinol Metab . 1997;  82 3597-3602
    CrossrefPubMedGoogle Scholar
  • 41 White D, Polson D, Kiddy D. Induction of ovulation with low-dose gonadotropins in polycystic ovary syndrome: an analysis of 109 pregnancies in 225 women.  J Clin Endocrinol Metab . 1996;  81 3821-3824
    CrossrefPubMedGoogle Scholar
  • 42 Homburg R, Levy T, Berkovitz D. Gonadotropin-releasing hormone agonist reduces the miscarriage rate for pregnancies achieved in women with polycystic ovarian syndrome.  Fertil Steril . 1993;  59 527-531
    PubMedGoogle Scholar
  • 43 Balen A, Tan S, MacDougall J, Jacobs H. Miscarriage rates following in-vitro fertilization are increased in women with polycystic ovaries and reduced by pituitary desensitization with buserelin.  Hum Reprod . 1993;  8 959-964
    PubMedGoogle Scholar
  • 44 Campo S. Ovulatory cycles, pregnancy outcome and complications after surgical treatment of polycystic ovary syndrome.  Obstet Gynecol Surv . 1998;  53 297-308
    CrossrefPubMedGoogle Scholar
  • 45 Amar N, Lachelin G. Laparoscopic ovarian diathermy: an effective treatment for anti-oestrogen resistant anovulatory infertility in women with the polycystic ovary syndrome.  Br J Obstet Gynaecol . 1993;  100 161-164
    PubMedGoogle Scholar
  • 46 Donesky B, Adashi E. Surgically induced ovulation in the polycystic ovary syndrome: wedge resection revisited in the age of laparoscopy.  Fertil Steril . 1995;  63 439-463
    PubMedGoogle Scholar
  • 47 Kiddy D S, Hamilton-Fairley D, Bush A. et al . Improvement in endocrine and ovarian function during dietary treatment of obese women with polycystic ovary syndrome.  Clin Endocrinol (Oxf) . 1992;  36 105-111
    CrossrefPubMedGoogle Scholar
  • 48 Velazquez E M, Mendoza S G, Wang P, Glueck C J. Metformin therapy is associated with a decrease in plasma plasminogen activator inhibitor-1, lipoprotein(a), and immunoreactive insulin levels in patients with the polycystic ovary syndrome.  Metabolism . 1997;  46 454-457
    CrossrefPubMedGoogle Scholar
  • 49 Hasegawa I, Murakawa H, Suzuki M. Effect of troglitazone on endocrine and ovulatory performance in women with insulin resistance-related polycystic ovary syndrome.  Fertil Steril . 1999;  71 323-327
    CrossrefPubMedGoogle Scholar
  • 50 Azziz R, Ehrmann D, Legro R S. et al . Troglitazone improves ovulation and hirsutism in the polycystic ovary syndrome: a multicenter, double blind, placebo-controlled trial.  J Clin Endocrinol Metab . 2001;  86 1626-1632
    CrossrefPubMedGoogle Scholar
  • 51 Nestler J, Jakubowicz D, Evans W, Pasquali R. Effects of metformin on spontaneous and clomiphene-induced ovulation in the polycystic ovary syndrome.  N Engl J Med . 1998;  338 1876-1880
    PubMedGoogle Scholar
  • 52 Inzucchi S E, Maggs D G, Spollett G R. et al . Efficacy and metabolic effects of metformin and troglitazone in type II diabetes mellitus.  N Engl J Med . 1998;  338 867-872
    CrossrefPubMedGoogle Scholar
  • 53 Ehrmann D, Cavaghan M, Imperial J, Sturis J, Rosenfield R, Polonsky K. Effects of metformin on insulin secretion, insulin action, and ovarian steroidogenesis in women with polycystic ovary syndrome.  J Clin Endocrinol Metab . 1997;  82 524-530
    PubMedGoogle Scholar
  • 54 Nestler J E, Jakubowicz D J. Decreases in ovarian cytochrome P450c17 alpha activity and serum free testosterone after reduction of insulin secretion in polycystic ovary syndrome.  N Engl J Med . 1996;  335 617-623
    CrossrefPubMedGoogle Scholar
  • 55 Nestler J E, Stovall D, Akhter N, Iuorno M J, Jakubowicz D J. Strategies for the use of insulin-sensitizing drugs to treat infertility in women with polycystic ovary syndrome.  Fertil Steril . 2002;  77 209-215
    CrossrefPubMedGoogle Scholar
  • 56 Dunaif A, Scott D, Finegood D, Quintana B, Whitcomb R. The insulin-sensitizing agent troglitazone improves metabolic and reproductive abnormalities in the polycystic ovary syndrome.  J Clin Endocrinol Metab . 1996;  81 3299-3306
    CrossrefPubMedGoogle Scholar
  • 57 Ehrmann D, Schneider D, Sobel B. et al . Troglitazone improves defects in insulin action, insulin secretion, ovarian steroidogenesis, and fibrinolysis in women with polycystic ovary syndrome.  J Clin Endocrinol Metab . 1997;  82 2108-2116
    CrossrefPubMedGoogle Scholar